Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

This study has been completed.

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

AstraZeneca

ClinicalTrials.gov Identifier:

NCT01029886

First received: December 8, 2009

Last updated: June 6, 2014

Last verified: June 2014

History of Changes

Results First Received: February 14, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Type 2 Diabetes Mellitus
Interventions:	Drug: exenatide once weekly Drug: liraglutide

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Exenatide Once Weekly	Subcutaneous injection, 2mg, once weekly
Liraglutide Once Daily	Subcutaneous injection, forced titration to 1.8mg, once daily
Total	Total of all reporting groups

Baseline Measures

	Exenatide Once Weekly	Liraglutide Once Daily	Total
Number of Participants [units: participants]	461	450	911
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	386	360	746
>=65 years	75	90	165
Age [units: years] Mean ± Standard Deviation	56.6 ± 9.43	56.7 ± 9.59	56.6 ± 9.51
Gender [units: participants]
Female	207	205	412
Male	254	245	499
Glycosylated hemoglobin (HbA1c) [units: percentage of total hemoglobin] Mean ± Standard Deviation	8.45 ± 1.014	8.43 ± 0.996	8.44 ± 1.004
Weight [units: kg] Mean ± Standard Deviation	90.88 ± 19.472	91.13 ± 19.118	91.00 ± 19.288
Background Oral Antidiabetic Agent (OAD) [units: participants]
Metformin (MET)	150	136	286
Sulfonylurea (SU)	18	18	36
Pioglitazone (PIO)	1	0	1
MET+SU	275	277	552
MET+PIO	16	18	34
MET+SU+PIO	1	1	2

Outcome Measures

Show All Outcome Measures

1. Primary:

Change in HbA1c From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 1

2. Secondary:

Percentage of Patients Achieving HbA1c <7.0% at Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 2

3. Secondary:

Change in Fasting Serum Glucose From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 3

4. Secondary:

Change in Body Weight From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 4

5. Secondary:

Change in Total Cholesterol From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 5

6. Secondary:

Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 6

7. Secondary:

Ratio of Fasting Triglycerides at Week 26 to Baseline [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 7

8. Secondary:

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Show Outcome Measure 8

9. Secondary:

Change in Diastolic Blood Pressure (DBP) From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Hide Outcome Measure 9

Measure Type	Secondary
Measure Title	Change in Diastolic Blood Pressure (DBP) From Baseline to Week 26
Measure Description	Change in DBP from baseline to the treatment endpoint at Week 26.
Time Frame	Baseline, Week 26
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT Population. All observed data from all scheduled visits (including early termination visits) were included in the MMRM analysis. Data collected at the early termination visits were mapped into the following scheduled visits.

Reporting Groups

	Description
Exenatide Once Weekly	Subcutaneous injection, 2mg, once weekly
Liraglutide Once Daily	Subcutaneous injection, forced titration to 1.8mg, once daily

Measured Values

	Exenatide Once Weekly	Liraglutide Once Daily
Number of Participants Analyzed [units: participants]	404	398
Change in Diastolic Blood Pressure (DBP) From Baseline to Week 26 [units: mmHg] Least Squares Mean ± Standard Error	-0.49 ± 0.37	-0.51 ± 0.37

Statistical Analysis 1 for Change in Diastolic Blood Pressure (DBP) From Baseline to Week 26

Groups ^[1]	All groups
Method ^[2]	Mixed Models Analysis
P Value ^[3]	0.981
Least Squares Mean Difference ^[4]	0.01
Standard Error of the mean	± 0.50
95% Confidence Interval	( -0.96 to 0.98 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	MMRM model includes treatment, baseline DBP, HbA1c stratum, country, background OAD, week of visit, and treatment-by-week interaction as fixed effects and subject and error as random effects.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.
[4]	Other relevant estimation information:
	No text entered.

10. Secondary:

Assessment of Event Rate of Treatment-emergent Hypoglycemic Events [ Time Frame: Baseline to Week 26 ]

Show Outcome Measure 10

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Show More Information

To Top